The role of patiromer: Comparing OPAL-HK data with untreated real-world patients in the United Kingdom—A retrospective, propensity-matched analysis

OBJECTIVES: The first phase of the published OPAL-HK study was a single-group treatment phase, which showed that patiromer normalised serum potassium at 4weeks in patients with chronic kidney disease stages 3–4 who were receiving renin-angiotensin-aldosterone inhibitors. We utilised real-world data...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Ibrahim, Chinnadurai, Rajkumar, Cornea, Georgiana, Intorcia, Michele, Kalra, Philip A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451519/
https://www.ncbi.nlm.nih.gov/pubmed/32853209
http://dx.doi.org/10.1371/journal.pone.0237467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451519/
https://www.ncbi.nlm.nih.gov/pubmed/32853209
http://dx.doi.org/10.1371/journal.pone.0237467

Ejemplares similares